ArticleFunctional & integrative genomics2026
Integration of clinical and cellular lipidomics identifies a serum metabolite signature predictive of oxaliplatin resistance in colorectal cancer.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOxaliplatin resistance remains a major obstacle in colorectal cancer (CRC) treatment. Lipid metabolism reprogramming is increasingly implicated in chemoresistance, but the clinically applicable lipid biomarkers are lacking.
methodsWe performed untargeted lipidomic profiling using LC–MS/MS on serum from 60 CRC patients (30 chemotherapy-sensitive, 30 -resistant) and an CRC cell (oxaliplatin-sensitive vs. -resistant). Differentially expressed metabolites (DEMs) were screened, and overlapping DEMs were prioritized using Random Forest and LASSO regression. A predictive signature was developed and validated in an independent cohort of 80 patients. Oxaliplatin was used to treat the CRC cells and validate the metabolite levels.
resultsWe identified 238 and 79 DEMs in serum and cells, respectively. Intersection and machine learning selected three metabolites, including: docosapentaenoic acid (DA), 7-(1-imidazolyl) heptanoic acid (IHA), and dihydroxyacetone phosphate (DHAP). The predictive signature achieved AUC of 0.806 (discovery) and 0.838 (validation), with excellent calibration and positive net benefit on decision curve analysis. The signature scores were significantly higher in patients with distant metastasis or advanced tumor stage, suggesting a link between metabolic dysregulation and disease progression. The signature was independent of conventional tumor markers. The experiment of oxaliplatin- resistant cells revealed that these three metabolites exhibited little influence by treatment of oxaliplatin.
conclusionThis integrative lipidomics approach yields a robust serum signature for predicting oxaliplatin resistance in CRC, with potential to reflect both therapeutic response and tumor aggressiveness.
Indexed as
Identifiers
41979739What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.